Recorded Presentation from the NCCN Pharmacy Updates: Current Challenges with Investigational Drug Services and Expanded Access Programs
It is necessary to identify the practice gaps in investigational drug services and provide solutions for better process improvement in managing clinical trials. In addition, it is important for pharmacists to be familiar with the steps that are involved in initiating expanded access programs and determine the criteria for successful enrollment and implementation of such programs.
Category
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Recorded Presentation from the NCCN Pharmacy Updates: Understanding the Place in Therapy for an Oral LHRH Antagonist as a Treatment Option in Prostate Cancer
Relugolix has a unique place in therapy for the treatment of prostate cancer. As a first-in-class oral LHRH antagonist, relugolix provides many benefits for patients. However, it is critical to understand how to manage the potential toxicities, drug interactions and adherence issues when initiating and maintaining this new oral agent.
Category
  • Prostate Cancer
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Recorded Presentation from the NCCN Pharmacy Updates: Not Just a Band-Aid: The Impact of Chemotherapy Dose Banding in Infants
It is important for health care professionals caring for pediatric patients with cancer to identify challenges in chemotherapy dosing for infants and smaller children, rationales for current dosing recommendations commonly utilized in clinical trials, and the potential impact of BSA-based dose banding in this specific subset of the pediatric patient population.
Category
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Recorded Presentation from the NCCN Pharmacy Updates: Crossroads of Exercise and Chemotherapy
It is important to provide education and an action plan to outline how exercise may not only reduce side effects from chemotherapy but also help chemotherapy work better and improve survival. As new data emerges, more specific exercise “doses” can be prescribed.
Category
  • Supportive Care Topics
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Archived Monthly Oncology Tumor Boards: Brain Metastases in Breast Cancer
Clinicians may be challenged when considering a trial of upfront systemic therapy alone for brain metastases, and a multidisciplinary discussion between medical and radiation oncology is recommended.
Category
  • Breast Cancer
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • CCM clock hours
  • Participation
Archived Monthly Oncology Tumor Boards: New Options in Treatment of Relapsed/Refractory Multiple Myeloma
In order to optimize patient outcomes, clinicians need to understand the evidence behind the current recommendations in the guidelines, the rationale for appropriate treatment selection, management of any treatment- or MM-specific adverse events, and emerging strategies.
Category
  • Multiple Myeloma
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • CCM clock hours
  • Participation
Archived Monthly Oncology Tumor Boards: Diagnosis and Management of Marginal Zone Lymphomas
Marginal zone lymphomas (MZLs) represent a clinical challenge due to their heterogeneity, and the relative rarity of individual subtypes has largely precluded the use of standard treatment approach across all subtypes. Educating clinicians about the biology of MZLs, novel therapeutic approaches, and special considerations will help them to develop an individualized treatment plan to optimize clinical outcomes.
Category
  • Non-Hodgkin's Lymphoma
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • CCM clock hours
  • Participation
Archived Monthly Oncology Tumor Boards: Update on New Treatments for Biliary Tract Cancers
While relatively rare, biliary tract cancers have a poor prognosis. Recently, molecular profiling has become increasingly useful as some new targeted therapies received FDA approval. It is important for clinicians to keep abreast of new and upcoming therapies in order to develop an optimal treatment strategy.
Category
  • Hepatobiliary Cancers
  • Hepatocellular Carcinoma
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • CCM clock hours
  • Participation
Archived Monthly Oncology Tumor Boards: New Targeted Therapies for Non-Small Cell Lung Cancer
This tumor board will discuss how to select the most appropriate therapy for patients with non-small cell lung cancer (NSCLC) using a case-based format. New targeted therapy regimens are being rapidly approved for patients with metastatic NSCLC and have been shown to improve outcomes for these patients.
Category
  • Lung Cancers
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • CCM clock hours
  • Participation
Clinical Scenario #1: Applying Biomarkers in Metastatic Non-Small Cell Lung Cancer
This activity will address the increasing use of biomarker testing in the management of patients with non-small cell lung cancer, the factors affecting the selection of the appropriate tests, challenges of interpreting test results and communicating the results to patients, and new developments in biomarker testing.
Category
  • Lung Cancers
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation

Pages